Please login to the form below
MET inhibitor
This page shows the latest MET inhibitor news and features for those working in and with pharma, biotech and healthcare.
AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China
AstraZeneca (AZ) and HUTCHMED have received the first regulatory approval for their oral MET inhibitor Orpathys with an authorisation from China’s National Medical Product Administration (NMPA) for a rare type ... In March 2020, Merck KGaA’s oral
Latest news
-
Lilly reports positive data from its phase 3 ulcerative colitis trial
The IL-23 inhibitor also met all key secondary endpoints compared to placebo at week 12, including reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic ... For Crohn’s,
-
Keytruda improves survival in first-line oesophageal cancer
The PD-L1 inhibitor met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the study, and improved outcomes compared to the current standard of care. ... treatment. In the phase 3 ATTRACTION-3 trial, which evaluated
-
Merck gets first approval for MET inhibitor tepotinib in Japan
First worldwide approval for MET inhibitor. Japan’s medicines regulator has approved Merck KGaA’s oral MET inhibitor tepotinib for non-small cell lung cancer with MET exon 14 (METex14) mutations, ... The Japanese approval is the first worldwide for
-
Incyte’s JAK inhibitor cream clears second eczema trial
The reformulation could open up a new and very large treatment category for the drug, as well as new territory for the JAK inhibitor class. ... The oral JAK inhibitor market is split between drugs used to treat cancer, like Jakafi, and those used for
-
Novartis pulls ahead of Merck in MET-positive lung cancer race
FDA starts priority review of Swiss pharma's MET inhibitor. Novartis’ MET inhibitor capmatinib could be approved for marketing in the US within six months for a rare form of ... The start of the review puts Novartis in a position to bring a drug for MET
Lilly reports positive data from its phase 3 ulcerative colitis trial
Keytruda improves survival in first-line oesophageal cancer
Merck gets first approval for MET inhibitor tepotinib in Japan
Incyte’s JAK inhibitor cream clears second eczema trial
Novartis pulls ahead of Merck in MET-positive lung cancer race
More from news
Approximately 3 fully matching, plus 32 partially matching documents found.
Latest appointments
-
AZ appoints Susan Galbraith as executive vice president, oncology R&D
This includes PARP inhibitor Lynparza (olaparib), third-generation tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib), the recently approved MET inhibitor Orpathys (savolitinib) and Koselugo (selumetinib) – indicated for the treatment of
AZ appoints Susan Galbraith as executive vice president, oncology R&D
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital strategist
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital project manager
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Onyx Health Launch Creative Studio After Record Year
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Paving the way for the HCP omnichannel experience: a guide for medical affairs
- EU approves bluebird bio’s CALD gene therapy Skysona
- Ashfield Health announces three new senior hires
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
